Raloxifene lowers IGF-I levels in acromegalic women

European Journal of Endocrinology

Volumn 148, Issue 4, 2003, Pages 443-448

  Attanasio, Roberto ^a   Barausse, Michela ^a   Cozzi, Renato ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CORTISONE ACETATE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; LEVOTHYROXINE; OCTREOTIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; NEUROSURGERY; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ACROMEGALY; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; PILOT PROJECTS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0038407910     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1480443     Document Type: Article

References (43)

1. Melmed S, Jackson I, Kleinberg D & Klibanski A. Current treatment guidelines for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 2646-2652.
2. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A et al. for the Acromegaly Treatment Consensus Workshop participants. Consensus Guidelines for Acromegaly Management. Journal of Clinical Endocrinology and Metabolism 2002 87 4054-4058.
3. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
4. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, DaRe N et al. Cabergoline treatment in acromegaly: a renewed role for dopamine agonist? European Journal of Endocrinology 1998 139 516-521.
5. Giusti M, Gussoni G, Cuttica CM & Giordano G & the Italian multicentre Slow Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicentre study. Journal of Clinical Endocrinology and Metabolism 1996 81 2089-2097.
6. Stewart PM, Kane KF, Stewart SE, Lancranjan I & Sheppard MC. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3267-3272.
7. Bates AS, Van't Hoff W, Jones JM & Clayton RN. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993 86 293-299.
8. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102.
9. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN & Van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. American Journal of Medicine 1980 69 571-575.
10. Cozzi R, Attanasio R, Oppizzi G, Orlandi P, Giustina A, Lodrini S et al. Effects of tamoxifen on GH and IGF-I levels in acromegaly. Journal of Endocrinological Investigation 1997 20 445-451.
11. Clemett D & Spencer CM. Raloxifene: a review of its use in post-menopausal osteoporosis. Drugs 2000 60 379-411.
12. Couse JF, Lindzey J, Grandien K, Gustafsson JA & Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 1997 138 4613-4621.
13. Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C & Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. Journal of Clinical Endocrinology and Metabolism 2001 86 2763-2768.
14. Torrisi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A et al. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. British Journal of Cancer 2001 85 1838-1841.
15. Metzger DL & Kerrigan JR. Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence. Journal of Clinical Endocrinology and Metabolism 1994 79 513-518.
16. Lahti EI, Knip M & Laatikainen TJ. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 1994 74 618-624.
17. Shupnik MA, Pitt LK, Soh AY, Anderson A, Lopes MB & Laws ER Jr. Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 3965-3972.
18. Chaidarun SS, Swearingen B & Alexander JM. Differential expression of estrogen receptor-beta (ERbeta) in human pituitary tumors: Functional interactions with ERalpha and a tumor-specific splice variant. Journal of Clinical Endocrinology and Metabolism 1998 83 3308-3315.
19. Huynh H & Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochemical Biophysical Research Communications 1994 203 253-259.
20. Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P & Matthias P. Estrogen receptor (ER)-alpha, but not ER-beta, mediates regulation of the insulin-like growth factor I gene by antiestrogens. Journal of Biological Chemistry 2001 276 35444-35449.
21. Veldhuis JD, Evans WS, Bowers CY & Anderson S. Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2. Endocrine 2001 14 45-62.
22. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM & Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996 81 2848-2853.
23. Kam GY, Leung KC, Baxter RC & Ho KK. Estrogens exert route-and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. Journal of Clinical Endocrinology and Metabolism 2000 85 1918-1922.
24. Cano A, Castelo-Branco C & Tarin JJ. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertility and Sterility 1999 71 261-267.
25. Paassilta M, Karjalainen A, Kervinen K, Savolainen MJ, Heikkinen J, Backstrom A-C et al. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: Relation to lipoprotein(a) levels. Atherosclerosis 2000 149 157-162.
26. Cardim HJP, Lopes CMC, Giannella-Neto D, Da Fonseca AM & Pinotti JA. The insulin-like growth factor-I system and hormone replacement therapy. Fertility and Sterility 2001 75 282-287.
27. Weissberger AJ, Ho KK & Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1991 72 374-381.
28. Anderson SM, Shah N, Evans WS, Patrie JT, Bowers CY & Veldhuis JD. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2001 86 551-560.
29. Moe KE, Prinz PN, Larsen LH, Vitiello MV, Reed SO & Merriam GR. Growth hormone in postmenopausal women after long-term oral estrogen replacement therapy. Journal of Gerontology (Series A-Biological Science & Medical Science) 1998 53 B117-B124.
30. Heald A, Selby PL, White A & Gibson JM. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. American Journal of Obstetrics and Gynecology 2000 183 593-600.
31. Bellantoni MF, Harman SM, Cho DE & Blackman MR. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages. Journal of Clinical Endocrinology and Metabolism 1991 72 172-178.
32. Hartmann B, Kirchengast S, Albrecht A, Laml T, Bikas D & Huber J. Effects of hormone replacement therapy on growth hormone secretion patterns in correlation to somatometric parameters in healthy postmenopausal women. Maturitas 1995 22 239-246.
33. Friend KE, Hartman ML, Pezzoli SS, Clasey JL & Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - A clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996 81 2250-2256.
34. Shah N, Evans WS, Bowers CY & Veldhuis JD. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2000 85 2649-2659.
35. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD & Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower post-glucose nadir GH concentrations in men than in women. Journal of Clinical Endocrinology and Metabolism 1994 78 1312-1319.
36. Giustina A, Bollati A, Bonfanti C, Licini M, Ragni G, Misitano V et al. Effects of estrogen receptor modulation by tamoxifen on growth hormone secretion in cultured human GH secreting pituitary adenoma cells. Journal of Endocrinological Investigation 1996 19 (Suppl) Abstract 30.
37. Tannenbaum GS, Gurd W, Lapointe M & Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 1992 130 3395-3401.
38. Attanasio R, Cozzi R, Oppizzi G, Dallabonzana D, Chiodini I, Benini Z et al. Persistence of somatostatinergic tone in acromegaly. European Journal of Endocrinology 1995 132 27-31.
39. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
40. Le Roith D, Bondy C, Yakar S, Liu JL & Butler A. The Somatomedin Hypothesis: 2001. Endocrine Reviews 2001 22 53-74.
41. Scheidegger KJ, Cenni B, Picard D & Delafontaine P. Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells: Mechanisms for its atheroprotective effects. Journal of Biological Chemistry 2000 275 38921-38928.
42. Raudaskoski T, Knip M & Laatikainen T. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy. Menopause 1998 5 217-222.
43. Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C & Delmas PD. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1999 84 2390-2397.